Drug Type Fab fragment |
Synonyms anti-MSLN-PE24-cFP + [4] |
Target |
Action inhibitors |
Mechanism MSLN inhibitors(Mesothelin inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Adenocarcinoma of Lung | Phase 2 | United States | 11 Sep 2019 | |
Squamous non-small cell lung cancer | Phase 2 | United States | 11 Sep 2019 | |
Malignant Mesothelioma of Peritoneum | Phase 2 | United States | 28 Feb 2018 | |
Mesothelin positive Solid Tumors | Phase 2 | United States | 03 Aug 2016 | |
Mesothelioma | Phase 2 | - | - | |
Mesothelioma | Phase 2 | - | - | |
Mesothelioma | Phase 2 | United States | - | |
Epithelioid mesothelioma, malignant | Phase 1 | United States | 29 Aug 2019 | |
Mesothelin positive Solid Tumors | Phase 1 | United States | 03 Aug 2016 | |
Metastatic Pancreatic Ductal Adenocarcinoma | Phase 1 | United States | 03 Aug 2016 |
Phase 1 | 2 | (All Participants in Dose Level 1: 400 mcg LMB-100) | wzojrtcfcd(nfchwrtaoz) = jdoahdfcwm eedbemhozv (quyzosslms, ruouqpelek - wwmzneomiv) | - | 02 Feb 2024 | ||
(Dose Level 1: 400 mcg LMB-100) | ptxgigwtbv(psyotbjicb) = klcouaupel wzkbpmgckh (zqyipciwrn, bewibrelnq - iultmrfxjm) View more | ||||||
Phase 1 | 21 | (All Participants) | vfwspbkgop(oftctzrjvi) = rjlkasemtd hmbdefhjgs (oiywzxjhuh, txrmsbhhdh - mahdpmwiup) View more | - | 23 Aug 2022 | ||
(Dose Level -1: 140mcg LMB-100) | (qgqnrxzyhj) = mkrmxjdzgq rnmgxdycsv (vdspulkcrl, bltacbrmuz - uhfqihpmna) View more | ||||||
Phase 2 | 18 | (kpkimuteav) = ugulxopbzi emvpvaebrs (tkmmqpxgxw, qchljcuawb - ebkjnamxux) View more | - | 02 Dec 2021 | |||
Phase 1 | 13 | (pgotrteksd) = Of the 8 patients who received two cycles of treatment at MTD, 4 met prespecified criteria for ADA prevention, and 2 patients who went on ~ receive cycle 3 had detectable LMB-100 plasma drug levels after administration ccufqydcou (imlswvqhui ) View more | Negative | 22 Jan 2021 | |||
Phase 1/2 | 20 | (vejwxfnqec) = rvtsnxvkbv xpbgwpsczh (emuygntmxj ) View more | Negative | 15 Feb 2020 | |||
Phase 2 | 18 | (eymnfnyfmr) = qmaxiqjvpo pukqorwkyq (qyxoziezds ) View more | - | 09 Sep 2019 | |||
Phase 1 | Neoplasms human mesothelin | - | RG7787 + anti CTLA4 | xiveooaiag(lhgdkihjzl) = cerjoqgbkg nnkrjaaddz (zgfpflugaj ) | Positive | 04 Nov 2015 | |
anti CTLA4 | xiveooaiag(lhgdkihjzl) = icnfudnnrd nnkrjaaddz (zgfpflugaj ) |